Encorafenib API Suppliers & Bulk Manufacturers
Available Forms: API (drug substance)
Available Strengths: Supplied to an in-house or pharmacopoeial specification
Reference Brands: Braftovi
Category: Active Pharmaceutical Ingredient
Encorafenib is an oral BRAF kinase inhibitor used with other targeted drugs in melanoma, colorectal and lung cancer. It is sourced by formulators, CDMOs and research teams.
Manufacture or export Encorafenib API? List it or send an offer →
Product Description:
Encorafenib is a kinase inhibitor that targets mutated BRAF, a protein that drives uncontrolled cell growth in some tumours. It is approved with binimetinib for BRAF V600E or V600K-mutated unresectable or metastatic melanoma and for BRAF V600E-mutated metastatic non-small cell lung cancer, and with cetuximab, with or without fluorouracil-based chemotherapy, for BRAF V600E-mutated metastatic colorectal cancer (reference brand: Braftovi).
Specification at a glance
| Traded form | Free base; white to almost white powder, slightly soluble at pH 1 and insoluble from pH 3 upwards |
|---|---|
| CAS number | 1269440-17-6 |
| Molecular formula | C22H27ClFN7O4S |
| Molecular weight | 540.0 g/mol |
| Pharmacopoeia | No USP monograph yet: USP's small-molecule priority list (April 2024) names encorafenib as a candidate for a new monograph. No Ph. Eur., JP, BP or IP monograph found (unverified). Supplied to an in-house specification. |
Regulatory files and timing
The FDA list of Drug Master Files (third quarter 2026) shows 3 active Type II API DMFs for this molecule. Few filings usually means few qualified sources, so early contact with suppliers pays off. For Europe, ask whether the supplier holds a CEP or an EU ASMF and, for imports into the EU, a written confirmation.
Generic or biosimilar entry. United States: Patent expiry; entry not confirmed (2030 (2031 with pending PTE)). European Union: No confirmed date.
Handling and quality points
Encorafenib's solubility drops sharply as pH rises, so particle size and solid form should be agreed with the formulator because both affect dissolution. The molecule has one stereocentre in its side chain, so chiral purity belongs in the specification. Treat it as a potent anticancer compound and expect suppliers to provide containment and cleaning data, together with nitrosamine and mutagenic impurity assessments.
Send an API enquiry All specialty APIs
Brand names are trademarks of their respective owners and identify the reference medicine only. Information is general and was checked in October 2026; confirm specifications and filings with the supplier before purchase.
Encorafenib API — third party manufacturing & bulk supply
Encorafenib API is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Encorafenib API is supplied as API (drug substance) — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Encorafenib API listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Encorafenib API →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Ask for the GMP certificate, certificate of analysis and specification first. A US DMF letter of access, or an EU ASMF where one exists, will be needed for filings. Buyers also look for chiral purity data, a nitrosamine risk assessment and stability results covering the proposed retest period.
Because it is barely soluble above pH 2, small changes in crystal form or particle size can change dissolution. Ask which form the supplier makes, how it is confirmed (usually XRPD) and whether it stays stable on storage, and set a particle size limit that suits your capsule process.
Yes. PharmaTradz links licensed manufacturers, CDMOs and R&D teams to GMP-compliant encorafenib makers and reviews the paperwork before introductions. Your company stays anonymous until both sides decide to talk.
Related Products
Venetoclax API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Venclexta, Venclyxto
View DetailsOzanimod Hydrochloride API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Zeposia
View DetailsPasireotide API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Signifor, Signifor LAR
View DetailsRelugolix API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Orgovyx, Myfembree, Ryeqo
View DetailsCalcium Dobesilate Granules
Strength:
API Purity: 98% (on anhydrous basis)
Form: Granules/ Powder
Reference Brands:
View DetailsIsavuconazole
Strength:
High-purity API
Form: White to off-white crystalline powder
Reference Brands: Cresemba (US/EU)
View DetailsLevocarnitine API
Strength:
API Purity: 98% (on anhydrous basis) BP / EP / USP Standard
Form: Crystalline powder
Reference Brands: Carnitor (US/EU)
View DetailsDoxepin
Strength:
API Purity: 99% (on anhydrous basis)
Form: White to off-white crystalline powder
Reference Brands: Sinequan, Silenor (US)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit